BEHAVIORAL-EFFECTS OF ALPHA-2 ADRENOCEPTOR ANTAGONISTS AND THEIR INTERACTIONS WITH ETHANOL IN TESTS OF LOCOMOTION, EXPLORATION AND ANXIETY IN MICE

BEHAVIORAL-EFFECTS OF ALPHA-2 ADRENOCEPTOR ANTAGONISTS AND THEIR INTERACTIONS WITH ETHANOL IN TESTS OF LOCOMOTION, EXPLORATION AND ANXIETY IN MICE
复制标题

DOI:
10.1007/bf00442248
复制
发表时间:
1989-01-01
期刊:
影响因子:
3.4
通讯作者:
LINNOILA, M
LINNOILA, M
中科院分区:
医学3区
文献类型:
--
作者:
DURCAN, MJ;LISTER, RG;LINNOILA, M

文献摘要

被引文献

相似文献

采用迷宫焦虑试验和定向探索和自主活动的洞板试验,研究了两种高选择性α 2肾上腺素能受体拮抗剂阿替美唑和咪唑克生对小鼠行为的影响。在任何试验剂量下,均未观察到任何药物的致焦虑作用(通过进入plusmaze封闭臂而非开放臂的趋势进行评估)。在任何剂量的任一药物下,对运动活动或在洞板中的定向探索(头部浸入)或总plusmaze臂进入均无任何显著影响。阿替美唑或咪唑克生的联合给药对乙醇(2 g/kg)的抗焦虑作用或其在洞板中的运动刺激作用均无影响。阿替美唑(1.0和3.0 mg/kg)显著逆转了乙醇诱导的探头下降;在咪唑克生中观察到了类似的趋势。1.0 mg/kg阿替美唑和0.3和1.0 mg/kg咪唑克生对乙醇诱导的十字迷宫总臂进入数的增加也有显著的增强作用。结果表明,乙醇的一些行为效应可以逆转的α 2-肾上腺素受体拮抗剂,而其他的是不变的。
The behavioral effects of two highly selective alpha2-adrenoceptor antagonists, atipamezole and idazoxan, were investigated in mice using the plusmaze test of anxiety and the holeboard test of directed exploration and locomotor activity. No anxiogenic effect, as assessed by the tendency to enter the closed as opposed to open arms of the plusmaze, was noted for either drug at any dose tested. Neither were there any significant effects on locomotor activity or directed exploration (head-dipping) in the holeboard, or total plusmaze arm entries at any dose of either drug. The co-administration of either atipamezole or idazoxan had no effect on either the anxiolytic effect of ethanol (2 g/kg) or its locomotor stimulant effect in the holeboard. Atipamezole (1.0 and 3.0 mg/kg) significantly reversed the ethanol-induced reduction in exploratory head-dipping; a similar trend was seen for idazoxan. There was also a significant potentiation of the ethanol-induced increase in the number of total arm entries made on the plusmaze caused by 1.0 mg/kg (but not 3.0 mg/kg) atipamezole and both 0.3 and 1.0 mg/kg idazoxan. The results suggest that some of the behavioral effects of ethanol can be reversed by alpha2-adrenoceptor antagonists whilst others are unchanged.